Chikungunya Vaccine, Live
Trade name: IXCHIQ
VaccineapprovedBreakthrough Therapy FDA
Approved
Nov 9, 2023
Clinical trial activity
8 trials · 4 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
5
Phase 4
1
Earliest trial started Mar 5, 2018 (NCT03382964)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Chikungunya virusImmunity, active
immunity, active - chikungunya virus
Approval history
- approvedAcceleratedBreakthroughNov 9, 2023
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07133178 | Phase 3 | Feb 6, 2026 | Valneva |
| NCT06928753 | Phase 4 | Apr 18, 2025 | Centre Hospitalier Universitaire de la Réunion, Government of France, Université de La Réunion |
| NCT06106581 | Phase 2 | Dec 31, 2023 | Valneva |
| NCT06028841 | Phase 3 | Nov 30, 2023 | Valneva |
| NCT04838444 | Phase 3 | Apr 2, 2021 | Valneva |
| NCT04786444 | Phase 3 | Feb 22, 2021 | Valneva |
| NCT04546724 | Phase 3 | Sep 17, 2020 | Valneva |
| NCT03382964 | Phase 1 | Mar 5, 2018 | Valneva |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Valneva | For profit | 7 | 7 | 3 | 2018 |
| Centre Hospitalier Universitaire de la Réunion | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of France | Government | 1 | 0 | 1 | 2025 |
| Université de La Réunion | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Valneva | For profit | NDA | Nov 9, 2023 |